Joseph Marakovits
Therapeutics Clinical Research(US)Fate Therapeutics (United States)(US)
Publications by Year
Research Areas
Viral Infections and Immunology Research, Protein Kinase Regulation and GTPase Signaling, Peptidase Inhibition and Analysis, Signaling Pathways in Disease, Cancer-related Molecular Pathways
Most-Cited Works
- → Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth(2010)320 cited
- → Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes(1999)316 cited
- → Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P1 Lactam Moieties as l-Glutamine Replacements(1999)189 cited
- → Tricyclic Benzimidazoles as Potent Poly(ADP-ribose) Polymerase-1 Inhibitors(2002)152 cited
- → Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 2. Peptide Structure−Activity Studies(1998)111 cited
- → Structure-based design of novel human Pin1 inhibitors (I)(2009)106 cited
- → Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 1. Michael Acceptor Structure−Activity Studies(1998)92 cited
- → Structure-based design of novel human Pin1 inhibitors (II)(2010)86 cited
- → Discovery of Pyrroloaminopyrazoles as Novel PAK Inhibitors(2012)60 cited
- → Synthesis and Evaluation of Nitroheterocyclic Phosphoramidates as Hypoxia-Selective Alkylating Agents(2000)59 cited